Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843425 | PMC |
| http://dx.doi.org/10.21037/atm-2022-60 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimization of antidepressant treatment by pharmacogenomics: a case report.
BMC Psychiatry
January 2025
Institute of Mental Health, Peking University Sixth Hospital, Beijing, 100191, China.
Background: Few new psychiatric drugs have entered the market in recent decades; in contrast, the number of drugs carrying pharmacogenomic labels continues to increase. For the foreseeable future, the advancement of psychiatry and drug therapy may hinge on personalized treatment. Currently, antipsychotic or antidepressant choices rely heavily on the clinical experience of psychiatrists and potentially lengthy iterative trials.
View Article and Find Full Text PDFAssociation between methyl-CpG-binding domain protein 5 gene and depressive symptoms in Mexican population: Results from MxGDAR/Encodat cohort.
Braz J Psychiatry
January 2025
Data Analysis and Survey Unit, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico. Faculty of Psychology, Universidad Nacional Autónoma de México, Mexico, City, Mexico.
Objective: To explore the association between 75 candidate genes previously reported in subjects with anxiety symptoms (AS) and depressive symptoms (DS) in a Mexican cohort.
Methods: The sample included 2012 individuals from the Mexican Genomic Database for Addiction Research (MxGDAR/Encodat) cohort, 198 showed AS, 266 DS, 66 anxiety and depressive symptoms (ADS), and 1482 healthy controls. The DI-PAD screening questionnaire was used to evaluate lifetime AS and DS.
Hypothesized pharmacogenomic and medication influences on tetrahydrocannabinol and cannabidiol metabolism in a cohort of unselected oral cannabis users.
J Cannabis Res
January 2025
Division of General Internal Medicine, Mayo Clinic College of Medicine and Science, 200 First St SW, Rochester, MN, 55905, USA.
Background: Differences in cannabinoid metabolism and patient responses can arise even with equivalent doses and formulations. Genetic polymorphisms in genes responsible for cannabinoid metabolism and medications that alter CYP450 pathways responsible for metabolism of cannabinoids may account for some of this variability.
Materials And Methods: A retrospective chart review was conducted on a cohort of unselected patients who had previously completed pharmacogenomic testing and reported oral cannabis use, as defined as "oral" or "by mouth" route of administration.
Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective (2024).
Ann Acad Med Singap
December 2024
Institute of Mental Health, Singapore.
Introduction: Pharmacogenomic testing in psychiatry is an emerging area with potential clinical application of guiding medication choice and dosing. Interest has been fanned by commercial pharmacogenomic providers who have commonly marketed combinatorial panels that are direct-to-consumer. However, this has not been adopted widely due to a combination of barriers that include a varying evidence base, clinician and patient familiarity and acceptance, uncertainty about cost-effectiveness, and regulatory requirements.
View Article and Find Full Text PDFDPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy.
Cancer Chemother Pharmacol
January 2025
Service de Génomique des Tumeurs et Pharmacologie, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France.
The enzyme dihydropyrimidine dehydrogenase (DPD) is the primary catabolic pathway of fluoropyrimidines including 5 fluorouracil (5FU) and capecitabine. Cases of lethal toxicity have been reported in cancer patients with complete DPD deficiency receiving standard dose of 5FU or capecitabine. DPD is encoded by the pharmacogene DPYD in which more than 200 variants have been identified.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!